McKenna's Pharmacology for Nursing, 2e

992

Index

Protozoal infections continued care considerations, 174

Pulse pressure, 642, 651, 713, 714 PVCs (premature ventricular contractions), 696, 699, 700 Pyelonephritis, 819, 820 Pyramidal tract, 385, 387 Pyrantel, 183, 185, 186 Pyridostigmine, 487, 489, 493–495 Pyrimethamine, 172–174 Pyrogen, 229 Q Q fever, 279 Quality Use of Medicines (QUM) program, 65 Quetiapine, 336, 338, 344, 345 Quinagolide, 526 Quinapril, 662, 665 Quinidine, 704, 706, 707 Quinine, 167 R Rabeprazole, 900, 906–907 Rabies immunoglobulin, 286 Rabies vaccine, 281 Raloxifene, 606, 609, 614, 615 Raltegravir, 127, 137, 141–142 Raltitrexed, 200, 202 Ramipril, 662, 665 Ranitidine, 897, 900–903 RAS (reticular activating system), 298, 336, 347 Rasagiline, 382 Rasburicase, 198 Receptor theory of drug action, 17–18 Recombinant DNA technology, 258, 259 Red blood cell production, 799–800 Red clover, 613, 966 Red yeast rice, 966 Reference books, 11–12 Reflexes, gastrointestinal, 892–894 central, 893–894 local, 888, 892–893 Releasing factors, 514 Releasing hormones, 514 Remifentanil, 402 Renal system, 794–800 diuretics. See Diuretic agents kidneys. See Kidneys renal injury, 36 urinary tract. See Urinary tract Renin–angiotensin–aldosterone system, 652, 653, 657, 659, 794, 799 Repolarisation, 292, 294 Reproductive system, 596–604 female, 597–601 hormones, 598–599 menopause, 601 menstrual cycle, 599–600 Rashes, 33–34 Raspberry, 966 Reabsorption, 794, 797 Rebound congestion, 842, 846 Reboxetine, 331 Receptor response loss of, 17–18 Receptor sites, 16, 17

pregnancy, 8–9, 600–601 structures, 597–598 human sexual response, 603–604 male, 602–603 hormones, 601–603 structures, 602, 602 Reproductive system, female, drugs affecting, 606–624 adults, 608 children, 608 fertility drugs, 617–620 oestrogen receptor modulators, 614–616 care considerations, 615–616 older adults, 608 sex hormones, 607–614 care considerations, 615–616 uterine motility drugs, 620–624 oxytocics, 620–622 prostaglandins, 620, 622–624 Reproductive system, male, drugs affecting, 627–638 adults, 629 anabolic steroids, 627, 631–634 androgens, 627, 628–631 children, 629 drug–food interactions, 636 older adults, 629 penile erectile dysfunction, 627, 634–637 Resistance, 81, 84–85 acquiring, 84 bacterial, 84 preventing, 85 system, 642, 650 Respiration, 834, 836 Respiratory distress syndrome (RDS), 834, 839–840 Respiratory membrane, 834, 836, 837 Respiratory system, 834–840 fixed combination drugs, 877 lower respiratory tract, drugs acting on. See Lower respiratory tract, drugs acting on obstructive pulmonary disorders. See Pulmonary disorders, drugs used to treat pathophysiology, 837–840 lower respiratory tract conditions, 838–840 upper respiratory tract conditions, 837–838 structure and function, 835–837 gas exchange, 836–837 respiration, 837 upper respiratory tract, drugs acting on. See Upper respiratory tract, drugs acting on Respiratory viruses. See Influenza A and respiratory viruses, drugs for Retaplase, 757, 764 Reticular activating system (RAS). See RAS (reticular activating system) Reticulocyte, 774, 775 Rheumatoid arthritis, 241, 243, 244–245 Rhinitis medicamentosa, 842, 846

contraindications and cautions, 172–173 drug–drug interactions, 173–174 pharmacokinetics, 172 therapeutic actions and indications, 172 amoebiasis, 163, 170–171 care considerations, 174 cinchonism, 163 giardiasis, 163, 172 leishmaniasis, 163, 171 Pneumocystis carinii pneumonia, 163, 172 trichomoniasis, 163, 172 trypanosomiasis, 163, 172 Proxymetacaine hydrochloride, 958 Prozac, 327 Pseudoephedrine, 842, 847–849 Psychological factors drug effects and, 25, 27 Psychotherapeutic agents, 334–350 adults, 335 antimanic drugs, 344–347 adverse effects, 345 care considerations (persons receiving lithium), 346–347 contraindications and cautions, 344–345 drug–drug interactions, 345–346 pharmacokinetics, 344 therapeutic actions and indications, 344 antipsychotic/neuroleptic drugs, 334, 336–342 adverse effects, 341 care considerations, 342 contraindications and cautions, 340 critical thinking scenario, 343–344 cultural considerations, 340 drug–drug interactions, 341 pharmacokinetics, 339 therapeutic actions and indications, 339 central nervous system stimulants, 347–348 adverse effects, 348 care considerations, 348–349 contraindications and cautions, 348 drug–drug interactions, 348 pharmacokinetics, 348 therapeutic actions and indications, 348 children, 335 cultural considerations, 340 mental disorders and their classification, 335–336 older adults, 335, 340 Psyllium, 346, 688, 917, 919, 920, 966 Puberty, 596, 598 Pulmonary arterial hypertension, 664

Pulmonary circulation, 649–650 Pulmonary disorders. See Lower

respiratory tract, drugs acting on

Pulmonary oedema, 681, 683